LG 50042 | CAS#1703-31-7 | bioactive chemical

MedKoo Cat#: 598766 | Name: LG 50042

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LG 50042 is a bioactive chemical.

Chemical Structure

LG 50042

CAS#1703-31-7

Theoretical Analysis

MedKoo Cat#: 598766

Name: LG 50042

CAS#: 1703-31-7

Chemical Formula: C16H21NO7

Exact Mass: 339.1318

Molecular Weight: 339.34

Elemental Analysis: C, 56.63; H, 6.24; N, 4.13; O, 33.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

LG 50042; LG-50042; LG50042; LG 50,042; LG-50,042; LG50,042;

IUPAC/Chemical Name

2,6-dimethoxy-4-(morpholine-4-carbonyl)phenyl ethyl carbonate

InChi Key

SFVJZJHVCCHUGR-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H21NO7/c1-4-23-16(19)24-14-12(20-2)9-11(10-13(14)21-3)15(18)17-5-7-22-8-6-17/h9-10H,4-8H2,1-3H3

SMILES Code

O=C(N1CCOCC1)C2=CC(OC)=C(OC(OCC)=O)C(OC)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LG 50042 is a bioactive chemical.

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 339.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA, Henriksen K. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E24-33. doi: 10.1152/ajpendo.00121.2014. Epub 2014 May 6. PubMed PMID: 24801386. 2: Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. Eur J Pharmacol. 2015 Sep 5;762:229-38. doi: 10.1016/j.ejphar.2015.05.051. Epub 2015 May 28. PubMed PMID: 26027795. 3: Arakawa K, Maehara S, Yuge N, Ishikawa M, Miyazaki Y, Naba H, Kato Y, Nakao K. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidi n-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia. Pharmacol Res Perspect. 2016 Jun 10;4(4):e00241. doi: 10.1002/prp2.241. eCollection 2016 Aug. PubMed PMID: 28116094; PubMed Central PMCID: PMC5242175. 4: Miyake T, Honma Y, Urano T, Kato N, Suzumiya J. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells. Int J Oncol. 2015 Jul;47(1):315-24. doi: 10.3892/ijo.2015.2979. Epub 2015 Apr 30. PubMed PMID: 25936828. 5: Hjuler ST, Gydesen S, Andreassen KV, Pedersen SL, Hellgren LI, Karsdal MA, Henriksen K. The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity. Obesity (Silver Spring). 2016 Aug;24(8):1712-22. doi: 10.1002/oby.21563. Epub 2016 Jun 14. PubMed PMID: 27296301. 6: Hüttener M, Dietrich M, Paytubi S, Juárez A. HilA-like regulators in Escherichia coli pathotypes: the YgeH protein from the enteroaggregative strain 042. BMC Microbiol. 2014 Oct 25;14:268. doi: 10.1186/s12866-014-0268-5. PubMed PMID: 25343852; PubMed Central PMCID: PMC4210603. 7: Calò M, Marini H, Bitto A, Altavilla D, Polito F, Minutoli L, Lo Cascio P, Antoci S, Squadrito F. Protective effects of IRFI-042 in monensin induced neurotoxicity in chicks. Food Chem Toxicol. 2008 Nov;46(11):3528-33. doi: 10.1016/j.fct.2008.09.009. Epub 2008 Sep 13. PubMed PMID: 18834916. 8: Calò M, Altavilla D, Seminara P, Marini H, Minutoli L, Bitto A, Naccari F, Squadrito F. Inhibition of lipid peroxidation by IRFI 042, a vitamin E analogue, decreases monensin cardiotoxicity in chicks. Toxicol Appl Pharmacol. 2005 Oct 15;208(2):137-44. PubMed PMID: 16183387. 9: Mok T, Wu YL, Sadowski S, Zhang J, Rangwala R, Kush D, Lopes Gde L. 195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042. J Thorac Oncol. 2016 Apr;11(4 Suppl):S142. doi: 10.1016/S1556-0864(16)30304-5. Epub 2016 Apr 15. PubMed PMID: 27198333. 10: De Lima Lopes G, Wu YL, Sadowski S, Zhang J, Rangwala R, Kush D, Mok T. P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894): Track: Immunotherapy. J Thorac Oncol. 2016 Oct;11(10S):S244-S245. doi: 10.1016/j.jtho.2016.08.114. Epub 2016 Sep 22. PubMed PMID: 27676577. 11: Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol. 2008 Feb 2;580(1-2):116-21. Epub 2007 Oct 30. PubMed PMID: 18031725. 12: Altavilla D, Squadrito G, Minutoli L, Deodato B, Bova A, Sardella A, Seminara P, Passaniti M, Urna G, Venuti SF, Caputi AP, Squadrito F. Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovasc Res. 2002 Jun;54(3):684-93. PubMed PMID: 12031715. 13: Chaudhuri RR, Sebaihia M, Hobman JL, Webber MA, Leyton DL, Goldberg MD, Cunningham AF, Scott-Tucker A, Ferguson PR, Thomas CM, Frankel G, Tang CM, Dudley EG, Roberts IS, Rasko DA, Pallen MJ, Parkhill J, Nataro JP, Thomson NR, Henderson IR. Complete genome sequence and comparative metabolic profiling of the prototypical enteroaggregative Escherichia coli strain 042. PLoS One. 2010 Jan 20;5(1):e8801. doi: 10.1371/journal.pone.0008801. PubMed PMID: 20098708; PubMed Central PMCID: PMC2808357. 14: Yang J, Guo H, Ding S, Tao B, Zhang X. [Effect of the treatment acceptance on the perinatal outcomes in women with subclinical hypothyroidism, positive thyroid gland peroxidase antibody in early pregnancy]. Zhonghua Fu Chan Ke Za Zhi. 2015 Sep;50(9):652-7. Chinese. PubMed PMID: 26675390. 15: Kawakami K, Hattori M, Inoue T, Maruyama Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, Sassa T, Suzumiy J, Honma Y. A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem. 2012 Sep;12(7):791-800. PubMed PMID: 22263802. 16: Izquierdo M, Navarro-Garcia F, Nava-Acosta R, Nataro JP, Ruiz-Perez F, Farfan MJ. Identification of cell surface-exposed proteins involved in the fimbria-mediated adherence of enteroaggregative Escherichia coli to intestinal cells. Infect Immun. 2014 Apr;82(4):1719-24. doi: 10.1128/IAI.01651-13. Epub 2014 Feb 10. PubMed PMID: 24516112; PubMed Central PMCID: PMC3993394. 17: Izquierdo M, Alvestegui A, Nataro JP, Ruiz-Perez F, Farfan MJ. Participation of integrin α5β1 in the fibronectin-mediated adherence of enteroaggregative Escherichia coli to intestinal cells. Biomed Res Int. 2014;2014:781246. doi: 10.1155/2014/781246. Epub 2014 Aug 7. PubMed PMID: 25177698; PubMed Central PMCID: PMC4142158. 18: Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, Thibault R, Pichard C. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013 Feb 2;381(9864):385-93. doi: 10.1016/S0140-6736(12)61351-8. Epub 2012 Dec 3. PubMed PMID: 23218813. 19: Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013 Mar;12(3):244-52. doi: 10.1016/S1474-4422(12)70323-X. Epub 2013 Jan 23. PubMed PMID: 23352199; PubMed Central PMCID: PMC3684942. 20: Campo GM, Squadrito F, Ceccarelli S, Calò M, Avenoso A, Campo S, Squadrito G, Altavilla D. Reduction of carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant. Free Radic Res. 2001 Apr;34(4):379-93. PubMed PMID: 11328674.